Andrew Gengos - May 18, 2023 Form 3 Insider Report for Athira Pharma, Inc. (ATHA)

Role
Officer
Signature
/s/ Mark Worthington, Attorney-in-fact for Andrew Gengos
Stock symbol
ATHA
Transactions as of
May 18, 2023
Transactions value $
$0
Form type
3
Date filed
5/22/2023, 05:51 PM
Previous filing
Feb 24, 2022
Next filing
Jun 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ATHA No securities are beneficially owned 0 May 18, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ATHA No securities are beneficially owned May 18, 2023 Not applicable 0 $0.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Not applicable

Remarks:

Chief Financial Officer and Chief Business Officer